Skip to main content
$41.50 -$0.32 (-0.8%)

04:00 PM EDT on 10/03/22

Cassava Sciences, Inc. (NASDAQ:SAVA)

CAPS Rating: 1 out of 5

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Current Price $41.50 Mkt Cap $1.7B
Open $42.00 P/E Ratio 0.00
Prev. Close $41.50 Div. (Yield) $0.00 (0.0%)
Daily Range $39.70 - $42.77 Volume 1,684,264
52-Wk Range $13.84 - $100.00 Avg. Daily Vol. 4,710,182


How do you think NASDAQ:SAVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

193 Outperform
35 Underperform

All-Star Players

25 Outperform
11 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:SAVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFjimhalley (< 20)
Submitted July 12, 2021

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.

SmartAce (99.98)
Submitted August 27, 2018

My 5 year old son just asked “what if we put a slice of turkey in the DVD player and it played a movie about the turkey’s whole life” and none of the parenting books I’ve read have prepared me for this question.

Recent Community Commentary

Read the most recent pitches from players about SAVA.


Member Avatar TMFjimhalley (< 20) Submitted: 7/12/2021 6:46:55 PM : Outperform Start Price: $100.15 NASDAQ:SAVA Score: -42.59

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.


Member Avatar kfox (< 20) Submitted: 2/2/2021 4:28:30 PM : Outperform Start Price: $33.39 NASDAQ:SAVA Score: +28.43

They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.


Member Avatar capptten (< 20) Submitted: 11/30/2020 8:05:16 PM : Outperform Start Price: $7.66 NASDAQ:SAVA Score: +441.50

This is a high risk high reward stock. The company has changed the name to Cassava Science. The have completed a stage 2 study and raised and additional 75 million to bring cash up to about 94 million. This will allow them to do a stage 3 study which they will be meeting the FDA in January. The stage 2 showed improved many improved biomarkers and there were some stories of caregivers noticing improvement in some patients behaviors. All of this information is readily available. The company decided to raise the money to complete more studies than sell the at a discounted price. If this study goes well most feel that this company would be bought out in excess of $100 per share. I encourage you to read and do your own DD.


Find the members with the highest scoring picks in SAVA.

Score Leader


medeaschild (75.01) Score: +5,300.15

The Score Leader is the player with the highest score across all their picks in SAVA.

Member Name Member
Call Time
Score Commentary
medeaschild 75.01 12/26/2018 Outperform NS $0.76 +5,355.50% +55.35% +5,300.15 0 Comment
SmallCapSurfer2 71.13 10/13/2016 Outperform 3M $5.32 +680.08% +72.78% +607.29 0 Comment
capptten < 20 12/1/2020 Outperform 3M $7.66 +441.78% +0.28% +441.50 1 Comment
foolrrrrrrrrrr 34.20 11/13/2008 Underperform 1Y $37.61 +10.35% +345.05% +334.70 0 Comment
jornoski 28.85 9/21/2020 Outperform 5Y $9.45 +339.15% +12.55% +326.60 0 Comment
OklaBoston 48.43 9/21/2020 Outperform 3Y $9.45 +339.15% +12.55% +326.60 1 Comment
Dennyf10 57.87 10/16/2008 6/22/2009 Underperform 1Y $35.72 +16.17% +310.84% +294.68 0 Comment
marcet 74.20 3/2/2009 Underperform 3W $18.82 +120.46% +414.45% +293.99 0 Comment
hackerbobZ < 20 3/23/2009 Underperform 5Y $17.65 +135.09% +370.42% +235.33 0 Comment
deemonfather42 < 20 7/6/2009 Underperform 3W $22.42 +85.09% +311.88% +226.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SAVA.